STAT Plus: Nearly a year since opening its doors, here’s how Verily’s addiction medicine campus is taking shape
Verily drew widespread praise last year when it announced an “ambitious endeavor” to combat the…
Category: STAT Plus
STAT Plus: Pharmalittle: Trump promises a Covid-19 vaccine in 2020; WHO’s grand experiment is faltering
Good morning, everyone. Damian Garde here, filling in for Ed Silverman in the waning hours…
STAT Plus: New poll shows wide support for several Trump drug pricing reforms, but not rebate changes
WASHINGTON — Voters in several battleground states overwhelmingly support several of President Trump’s recent proposals…
STAT Plus: Employers are planning how to blunt the cost of pricey new specialty drugs
As the pharmaceutical industry develops increasingly expensive medicines – notably, those costing seven figures –…
STAT Plus: Pharmalittle: Trump launches a crusade against the FDA; Europe signs Covid-19 vaccine deal with AstraZeneca
Rise and shine, everyone, another busy day is on the way. The Pharmalot campus, for…
STAT Plus: Amazon debuts wrist wearable Halo, marking its entry into health tracking
Joining the ranks of other health tech giants, Amazon on Thursday debuted a wrist wearable…
.jpg)
STAT Plus: Foundation Medicine wins FDA approval for first liquid biopsy able to detect multiple cancers
The Food and Drug Administration on Wednesday approved the first comprehensive “liquid biopsy” platform that…
STAT Plus: Catalyst takes it fight over a rare disease drug to Canada, suing the country’s regulator
An unusual battle between two small companies over the market for a rare disease drug…
STAT Plus: Telehealth company Amwell files to sell shares to public, Google
American Well Corp., a Boston telehealth company known as Amwell, said it plans to sell…
STAT Plus: Pharmalittle: Covid-19 vaccine makers push EU for liability protections; pharma plans counteroffer to Trump
Good morning, everyone, and how are you today? Another busy day is unfolding here on…
STAT Plus: Drug industry lobbyists circulate two drug pricing proposals in hopes of warding off a Trump executive order
WASHINGTON — The pharmaceutical industry is weighing two drug pricing policies that it could offer…
STAT Plus: Cardinal Health is accused of running a ‘rent-a-vet’ scheme to win government contracts
The largest association of independent nuclear pharmacies in the U.S. is accusing Cardinal Health (CAH),…
STAT Plus: Pharmalittle: Hahn apologizes for statistical blunder; Fauci warns of approving a Covid-19 vaccine too soon
Top of the morning to you, and a fine one it is. Blue skies and…
STAT Plus: Acadia Pharmaceuticals buys pain drug maker, part of effort to expand on psychosis treatment
Acadia Pharmaceuticals is purchasing a small Texas startup, CerSci, for $52 million in order to…
STAT Plus: As Elon Musk’s Neuralink prepares to draw back the curtain, ex-employees describe rushed timelines clashing with science’s slow pace
The hype from Elon Musk has been coming for weeks: This Friday, his secretive brain-implants…
STAT Plus: Pharmacists say they tell patients about physical changes to pills, but consumers say that isn’t always the case
Most consumers say they aren’t notified of physical changes in their prescription pills, even though…
STAT Plus: Pharmalittle: FDA decision to OK Covid-19 plasma prompts skepticism; will Trump fast track AstraZeneca vaccine?
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: In the race for a Covid-19 vaccine, Pfizer turns to a scientist with a history of defying skeptics — and getting results
For the pharma behemoth Pfizer, the race to develop a Covid-19 vaccine is not just…
STAT Plus: Pharmalittle: FDA official would resign if agency pressured to OK Covid-19 vaccine; J&J plans huge vaccine trial
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Biomarin, Gilead drug rejections don’t signal a change in attitude at the FDA
It’s tempting to interpret the Food and Drug Administration’s surprise rejections of drugs from Gilead…
STAT Plus: Drug makers seek to curtail discounts paid to hospitals as part of a controversial federal program
A growing number of drug makers are taking steps to curtail the discounts they offer…
STAT Plus: Boehringer to pay $379,000 to settle charges of wage discrimination against female employees
Following a review by the Department of Labor, a unit of Boehringer Ingelheim agreed to…
STAT Plus: Pharmalittle: Mail slowdown could limit access to drugs; CureVac nears a Covid-19 vaccine deal with Europe
Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy…
STAT Plus: Stunning FDA rejection signals potential new hurdles for gene therapies
The Food and Drug Administration’s unexpected rejection of a gene therapy for the bleeding disorder…
STAT Plus: Otsuka approved to buy bankrupt smart-pill maker Proteus’ assets, overcoming effort by Novartis to block purchase
The Japanese drug maker Otsuka has been approved to purchase the assets of bankrupt smart…
STAT Plus: After FDA rejection of a key drug, is Gilead still a turnaround story?
The surprise decision by the FDA to reject a Gilead Sciences (GILD) drug for treating…
New research tabs a natural byproduct of metabolism as a potent trigger of cancer spread
Aging is the biggest risk factor for cancer: The older we get, the more likely…
STAT Plus: Pharmalittle: FDA surprises BioMarin and Gilead by rejecting key drugs; J&J pays $6.5 billion to buy Momenta
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
STAT Plus: Turning Point releases positive data for targeted cancer drug, points to more rapid FDA filing
Turning Point Therapeutics, a San Diego developer of targeted cancer drugs, released positive data Wednesday…
STAT Plus: In a shocking decision, FDA rejects BioMarin’s gene therapy for hemophilia
The Food and Drug Administration on Wednesday rejected a one-time therapy for hemophilia A, delaying…
STAT Plus: J&J to buy Momenta Pharma in a bid to bolster autoimmune disease pipeline
Health care giant Johnson & Johnson said Wednesday that it is acquiring Momenta Pharmaceuticals, gaining…
STAT Plus: An expected blockbuster drug from Gilead is rejected, imperiling the biotech’s future growth
Back before remdesivir became a household name, Gilead Sciences’ most-discussed drug was filgotinib, a treatment…
STAT Plus: Federal prosecutors allege Teva used charities to pay kickbacks to Medicare patients
Federal authorities alleged that Teva Pharmaceuticals (TEVA) donated hundreds of millions of dollars to a…
STAT Plus: FDA finalizes penalties for trial sponsors that don’t share data, but critics say the effort falls short
After a year of deliberation, the Food and Drug Administration released final guidelines for penalizing…
STAT Plus: Pharmalittle: Trump touts an unproven salve for Covid-19; states seek big bucks to settle opioid suits
Hello, everyone, and how are you today? A bright shiny sun and cool breezes are…
STAT Plus: How Teladoc won: The inside story of how well-timed bets propelled it ahead of the competition
The unquestioned leader in a virtual care sector that has surged in the Covid-19 era,…
STAT Plus: Applied Therapeutics’ muted response to a clinical hold speaks volumes
How a company communicates with investors can be just as meaningful as what it communicates….
STAT Plus: Opioid prescriptions written for Medicare Part D beneficiaries continues to drop
Amid an ongoing opioid crisis in the U.S., a new federal government report finds that…
STAT Plus: Q&A: Sanofi CEO Paul Hudson on a major acquisition, long-term strategy, and Covid-19 vaccines
It was less than 12 months ago that Paul Hudson took the reins at the…
STAT Plus: Pharmalittle: U.S. ties Covid-19 vaccine payments to milestones; Sanofi spends $3.7 billion for Principia and an MS drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Unity Biotechnology fails early test, raising doubts its ability to develop drugs to reverse aging symptoms
Unity Biotechnology said Monday that its experimental treatment for osteoarthritis failed to improve knee pain…
STAT Plus: CytoDyn is in financial and clinical distress, newly filed annual report shows
An annual report disclosed by CytoDyn on Friday night describes a drug maker in distress….
STAT Plus: Sanofi, aiming to speed MS treatment, to acquire Principia Biopharma for $3.68 billion
Sanofi said Monday that it is acquiring Principia Biopharma for $3.68 billion, giving the French…
STAT Plus: Medicaid beneficiaries sue Texas health agency for restricting access to hepatitis C medicines
A group of Medicaid enrollees is accusing a Texas agency of rationing hepatitis C medicines…
STAT Plus: CureVac’s value soars after IPO, as Covid-19 vaccine manufacturers become biotech’s hottest companies
The developer of a vaccine for Covid-19 saw its share price nearly triple within hours…
STAT Plus: Pharmalittle: Governments race to acquire Covid-19 vaccines; top Russian doctor quits over vaccine ethics
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Johnson & Johnson invests in Thirty Madison, signaling the resilience of pharma’s interest in health tech
Late last year, several high-profile partnerships between big pharma companies and health tech startups fell…
STAT Plus: Teladoc rival MDLive is preparing to go public next year
On the heels of Teladoc’s landscape-shifting deal to buy Livongo, telemedicine rival MDLive is setting…
STAT Plus: Doctors say antibiotic resistance is an issue — but most say they’re not part of the problem
Amid growing concerns over antibiotic resistance, a new survey finds the vast majority of doctors…
STAT Plus: Many psoriasis patients are paying higher prices than ever at the pharmacy counter
Over the past decade, wholesale prices for self-administered psoriasis medicines rose substantially, underscoring the ongoing…